[1] |
MA Fenghua, JIANG Anqi, CHEN Yiqing, XU Congjian, KANG Yu.
Magnetic resonance imaging for distinguishing gastric-type endocervical adenocarcinoma from lobular endocervical glandular hyperplasia
[J]. China Oncology, 2024, 34(4): 380-388.
|
[2] |
LIU Qi, CHANG Cai, LI Jiawei.
Research progress on the correlation between imaging features and the molecular subtype, histopathology, clinical prognosis of ductal carcinoma in situ of the breast
[J]. China Oncology, 2024, 34(2): 201-209.
|
[3] |
WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen.
Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma
[J]. China Oncology, 2023, 33(7): 693-700.
|
[4] |
TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022
[J]. China Oncology, 2023, 33(3): 191-200.
|
[5] |
CHEN Ruchuan, LIU Wei, ZHOU Bingni, LIU Xiaohang, ZHOU Liangping.
The value of VI-RADS combined with tumor contact length in the detection of muscle-invasive bladder cancer
[J]. China Oncology, 2023, 33(3): 260-266.
|
[6] |
SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei.
New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis
[J]. China Oncology, 2022, 32(4): 287-297.
|
[7] |
ZHOU Bingni, LIU Xiaohang, GU Bingxin, ZHOU Liangping, GU Yajia.
The value of mpMRI combined with 99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy
[J]. China Oncology, 2022, 32(2): 134-141.
|
[8] |
CAO Dalong, YE Dingwei.
New trends and future prospects of regulatory cell death in renal carcinoma
[J]. China Oncology, 2022, 32(10): 1000-1006.
|
[9] |
LEI Kunyang, XIE Wenjie, SUN Ting, LIU Yifu, WANG Xu.
Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma
[J]. China Oncology, 2022, 32(1): 34-40.
|
[10] |
LUO Rong , HU Peian , XIE Tiansong , ZHANG Zehua , ZHOU Liangping , ZHOU Zhengrong , CHEN Lei .
The correlation of imaging, clinical features and pathology of myxoid fibrosarcoma
[J]. China Oncology, 2021, 31(8): 734-739.
|
[11] |
HU Guannan , CHEN Lei , ZHOU Liangping , ZHOU Zhengrong .
A case report of pulmonary malignant melanoma complicated with lung adenocarcinoma and literature review
[J]. China Oncology, 2021, 31(7): 647-650.
|
[12] |
DONG Shijie, HU Xiaoxin, WANG Wei, YANG Meng, YUE Lei, TONG Tong, GU Yajia.
Prediction of lymph node metastasis of cervical cancer based on multi-sequence MRI and multi-system imaging omics model
[J]. China Oncology, 2021, 31(6): 460-467.
|
[13] |
TONG Ying, YU Yiwen, XIE Suhong, WANG Yanchun, LU Renquan, GUO Lin.
Effects of silent information regulator 4 overexpression or glutamine deprivation on apoptosis and proliferation of clear cell renal cell carcinoma
[J]. China Oncology, 2020, 30(6): 435-440.
|
[14] |
SUN Ruihong,WANG Xiang,SHEN Lijuan,MENG Fanhua,YIN Huabin .
Intravoxel incoherent motion parameters of breast cancer at MRI: effect of region of interest on parameter measurement consistency
[J]. China Oncology, 2019, 29(9): 700-708.
|
[15] |
CHEN Yang,YANG Qingsong,LU Jianping .
Differentiation of central gland prostate cancer from benign prostatic hyperplasia by using monoexponential and biexponential DWI models
[J]. China Oncology, 2019, 29(8): 583-589.
|